title: Impact of standard of care for psychosis in Parkinson disease.
authors.forename: T R
authors.initials: TR
authors.lastname: Thomsen
authors.forename: M
authors.initials: M
authors.lastname: Panisset
authors.forename: O
authors.initials: O
authors.lastname: Suchowersky
authors.forename: A
authors.initials: A
authors.lastname: Goodridge
authors.forename: T
authors.initials: T
authors.lastname: Mendis
authors.forename: A E
authors.initials: AE
authors.lastname: Lang
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000978:Antiparkinson Agents / Q000494:pharmacology; D014150:Antipsychotic Agents / Q000494:pharmacology; D005500:Follow-Up Studies; D006801:Humans; D008875:Middle Aged; D009462:Neurology / Q000592:standards*; D010300:Parkinson Disease / Q000150:complications* / Q000188:drug therapy / Q000628:therapy*; D011618:Psychotic Disorders / Q000150:complications* / Q000628:therapy*; D011785:Quality Assurance, Health Care; D013997:Time Factors
chemical_list: D000978:Antiparkinson Agents; D014150:Antipsychotic Agents